When people feel dismissed, confused or misaligned with their healthcare experience, they often quietly disengage long before that disengagement appears in the metrics pharma typically tracks.

The urgent patient question that goes unasked in the exam room, the follow up appointment that never gets scheduled, and the educational content that gets ignored are not isolated moments. They are moments of misconnection that can serve as early warning signs before disengagement appears later in delayed treatment initiation, reduced adherence, poor patient engagement, or dissatisfaction among HCPs, or other performance measures.

And solving for misconnection is not solely a communications fix; it is a way to identify trust breakdowns earlier, before they affect engagement, adoption, and outcomes.

The rapid pace of AI-driven health innovation should improve health experiences for all, but innovation alone cannot close the gap if people do not feel understood early enough to stay engaged. According to a report published by West Health Gallup Center on Healthcare,¹ only 28% of Americans strongly agree that their medical professionals know their health needs and care preferences. Another study found that 40% of physicians² expressed no confidence that their patients know how to find evidence-based health information online, and more than $500 billion³ in avoidable health care spending each year is attributed to medication management challenges.

Across the healthcare ecosystem, we have spent decades trying to solve for awareness, access, adherence, and trust.However, these data suggest we may need to move solutioning farther upstream. Health dignity, which is the experience of being seen, heard, and taken seriously in healthcare interactions, may offer pharma leaders a practical way to identify earlier communication indicators of disengagement before they become harder-to-reverse performance challenges.

Moments of misconnection are early warning signs

In analyzing⁴ more than 200 million digital sources and surveying 86 HCPs and 232 patients and caregivers, we found that 71% of respondents had a health dignity-defining experience. It also revealed an important perception gap between providers and patients suggesting that misconnection can be observed and measured before it hardens into disengagement.

While providers and patients surveyed are fairly aligned that taking concerns and symptoms seriously is a top priority, only 24% of healthcare providers said that listening without rushing matters most while 41% of patients believed this to be important. Low levels of health dignity are strongly associated with delayed care seeking, reduced engagement, and negative mental health impacts, reinforcing that communication breakdowns can signal future disengagement before traditional metrics capture it.

The most damaging breakdowns in healthcare experiences are often rooted in misalignment rather than intent, where patients, providers, and caregivers operate with different expectations of what it means to be seen, heard, and taken seriously. These moments accumulate, and can shape long-term perceptions and behaviors, making them valuable signals for pharma leaders who want to address communication breakdowns before they affect outcomes.

This reality illuminates why human connection should be viewed as a measurable business and health outcome driver, not simply a patient experience consideration, because it can help identify whether trust is being built or broken before lagging indicators reveal the damage.

What pharma leaders can measure before disengagement shows up

For pharmaceutical leaders, health dignity is not simply about addressing patient experience concerns. It translates human connection into a strategic advantage with implications for treatment initiation, adherence, health literacy, clinical trial participation, and ultimately whether scientific innovation effectively reaches the people it is intended to help. It is about considering which signals appear early enough to intervene, who current approaches are designed to reach successfully, who they fail, and what can be done to solve for the gaps.

As the healthcare landscape becomes more fragmented, it increases the risk of misconnection. Leaders who intentionally champion health dignity will be better positioned to improve the patient journey at scale by identifying where trust breaks down, where communication does not meet audience expectations, and where earlier intervention could improve engagement, adoption, and outcomes.

I’ve seen this lens improve how historically under-engaged audiences connect with branded and unbranded content. Showing up with the right culturally-informed activation can increase trust in a pharmaceutical company’s invitation to participate in clinical research or consider a treatment that may not have previously been on their radar.

Embedding health dignity signals into marketing and communications research, strategy, content, and experiences can help influence reputation, engagement, adoption and outcomes. That means using plain and culturally tailored language, better sequencing, expectation-setting, visit preparation tools, and privacy clarity while mirroring how audiences prefer to be engaged where they live, work, and play. It also means ensuring clinical research is designed to include the audiences that medicines are ultimately intended to treat, and that commercialization strategy is informed by patient journeys, human connection, and lived experience.

Shaping a more impactful future of health may not solely be about whether we can develop more effective medicines, faster algorithms, or more innovative patient engagement approaches. It may depend on whether people feel connected enough to use them, and whether pharma can identify moments of connection and misconnection early enough to address them before they show up as disengagement, lost trust, and poorer outcomes.

Sources

1. Contributor: Medication Adherence Is Not a Zero-Sum Game. AJMC, April 5, 2022. https://www.ajmc.com/view/contributor-medication-adherence-is-not-a-zero-sum-game
2. The Effect of Misinformation and Disinformation on Physicians’ Ability to Provide Quality Care. The Physicians Foundation. https://physiciansfoundation.org/research/the-effect-of-misinformation-and-disinformation-on-physicians-ability-to-provide-quality-care/
3. Contributor: Medication Adherence Is Not a Zero-Sum Game. AJMC. April 5, 2022. https://www.ajmc.com/view/contributor-medication-adherence-is-not-a-zero-sum-game
4. Health Dignity Needs to Shape the Future of Healthcare Experiences. Real Chemistry. March 12, 2026. https://www.realchemistry.com/health-dignity-needs-to-shape-the-future-of-healthcare-experiences/